Clinical analysis of tumor and non-tumor patients complicated with pulmonary embolism
- PMID: 26770488
- PMCID: PMC4694388
Clinical analysis of tumor and non-tumor patients complicated with pulmonary embolism
Abstract
Objective: To analyze the differences of the clinical characteristics and risk factors between tumor and non-tumor patients complicated with pulmonary embolism.
Methods: A retrospective analysis was conducted on 96 hospitalized patients complicated with pulmonary embolism admitted into 307 Hospital of PLA from January 2009 to December 2014. 96 cases were divided into tumor group (n=52) and non-tumor group (n=44) according to whether they were accompanied with malignant tumors. The relevant characteristics of tumor group, comparison of the risk factors and laboratory results between two groups were assessed.
Results: Lung cancer was prone to pulmonary embolism in malignant tumors and adenocarcinoma was the commonest pathological type. 31 (59.6%) cases developed pulmonary embolism within 3 months after tumor was diagnosed. The level of serum D-dimer and leukemia in tumor group were higher than that in non-tumor group (3241.06±4514.16 μg/L vs 1238.49±1236.69 μg/L and 9.68±5.53×10(9)/L vs 7.90±3.84×10(9)/L), with a significant statistical difference (P=0.004 and 0.015). The level of serum platlet in tumor group were lower than that in non-tumor group (204.63±132.58×10(9)/L vs 222.26±76.92×10(9)/L), with a significant statistical difference (P=0.023). Coronary heart disease, chronic lung disease, diabetes, hyperlipemia and cerebral infarction were significantly different between two groups (P<0.01). Unexplained dyspnea (51/96, 53.1%) was the main symptom of pulmonary embolism, yet no significant difference was found between the two groups. 33 cases (34.4%) combined with deep venous thrombosis of lower limb, right lower limb more than the left. Right main pulmonary artery and its branches embolism were seen in 46 cases (47.9%) according to imaging examination, and no significant difference between two groups. After thrombolytic and anticoagulant therapy, only 9 cases died of Pulmonary embolism.
Conclusion: There is no obvious and significant difference in clinical symptoms between tumor and non-tumor patients complicated with pulmonary embolism. Using of anticoagulant and thrombolytic therapy can obtain good curative effect upon diagnosis.
Keywords: D-dimer; Malignant tumor; pulmonary embolism.
Figures


Similar articles
-
[Clinical features of patients with venous thromboembolism: 177 case analysis in 10 years].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019 Apr;31(4):453-457. doi: 10.3760/cma.j.issn.2095-4352.2019.04.016. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31109420 Review. Chinese.
-
[Clinical characteristics of acute pulmonary embolism at different altitudes in plateau areas].Zhonghua Jie He He Hu Xi Za Zhi. 2019 Oct 12;42(10):755-759. doi: 10.3760/cma.j.issn.1001-0939.2019.10.008. Zhonghua Jie He He Hu Xi Za Zhi. 2019. PMID: 31594109 Chinese.
-
[Clinical characteristics of lung cancer complicated with pulmonary embolism].Zhonghua Jie He He Hu Xi Za Zhi. 2016 Mar;39(3):198-202. doi: 10.3760/cma.j.issn.1001-0939.2016.03.012. Zhonghua Jie He He Hu Xi Za Zhi. 2016. PMID: 26980534 Chinese.
-
[Early diagnosis of pulmonary embolism in patients with skin and soft tissue defects after trauma].Zhonghua Shao Shang Za Zhi. 2019 May 20;35(5):351-355. doi: 10.3760/cma.j.issn.1009-2587.2019.05.005. Zhonghua Shao Shang Za Zhi. 2019. PMID: 31154732 Chinese.
-
Acute pulmonary embolism.Dis Mon. 1994 Sep;40(9):467-523. Dis Mon. 1994. PMID: 8076500 Review.
Cited by
-
Clinical features of pulmonary embolism in patients with lung cancer: A meta-analysis.PLoS One. 2019 Sep 30;14(9):e0223230. doi: 10.1371/journal.pone.0223230. eCollection 2019. PLoS One. 2019. PMID: 31568496 Free PMC article.
-
Differential clinical manifestations and clinical outcome of cancer-related pulmonary embolism.Korean J Intern Med. 2020 Mar;35(2):360-368. doi: 10.3904/kjim.2018.267. Epub 2019 Aug 9. Korean J Intern Med. 2020. PMID: 31394894 Free PMC article.
-
Values of thoracic contrast-enhanced computed tomography in detecting incidental pulmonary thromboembolism in patients with malignant tumors.Oncol Lett. 2019 Jan;17(1):355-359. doi: 10.3892/ol.2018.9578. Epub 2018 Oct 15. Oncol Lett. 2019. PMID: 30655774 Free PMC article.
-
Primary pulmonary intravascular large B‑cell lymphoma misdiagnosed as pneumonia: Four case reports and a literature review.Oncol Lett. 2023 Apr 18;25(6):234. doi: 10.3892/ol.2023.13820. eCollection 2023 Jun. Oncol Lett. 2023. PMID: 37153040 Free PMC article.
-
Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review.J Cancer. 2018 Aug 6;9(17):3046-3057. doi: 10.7150/jca.26008. eCollection 2018. J Cancer. 2018. PMID: 30210627 Free PMC article. Review.
References
-
- Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–722. - PubMed
-
- Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol. 2007;25:5490–5505. - PubMed
-
- Chuang YM, Yu CJ. Clinical characteristics and outcomes of lung cancer with pulmonary embolism. Oncology. 2009;77:100–106. - PubMed
-
- Lee AY. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res. 2003;110:167–172. - PubMed
LinkOut - more resources
Full Text Sources